Table 4.
Summary of studies reported risk of development of sexual dysfunction comparing exposure to bupropion and SSRI/SNRI among depressed subjects.
| Study | NHMRC Evidence Hierarchy | Quality | Comparator | Dosage | Scale | Improvement in Sexual Functioning as a Whole | Improvement in Sexual Desire/ Interest | Depression |
|---|---|---|---|---|---|---|---|---|
| Thase 2006 [22] | Level II | 100% | Venlafaxine XR |
75-225mg | CSFQ | ↑* | ↑* | Yes |
| Kennedy 2006 [24] | Level II | 94% | Paroxetine | 20-40mg | CSFQ | ↔ | ↔ | Yes |
* p<0.05; ** p<0.01; *** p<0.001; ↑ improve; ↔ no difference statistically. NHMRC = Australian National Health and Medical Research Council. FSFI = Female Sexual Function Index; CSFQ = Changes in Sexual Functioning Questionnaire, ASEX = Arizona Sexual Experiences Scale, CGI-SF = Clinical Global Impression-Sexual Function and BISFW = Brief Index of Sexual Functioning for Women.